A less than ideal run from IXC with the FDA outcome. Hopefully they get the clarity they seek when they consult with the FDA. I am sure they will.
And then they still have to deal with potentially losing the rights to the drug all together. That would be a real kick in the guts for investors.
Let's hope this Exelogen issue goes away! It aint over yet though...
A less than ideal run from IXC with the FDA outcome. Hopefully...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
